Pauline L. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pauline L. Lee has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Ernest Beutler
Molecular and Experimental Medicine
17 shared publicationsCarol Halloran
8 shared publicationsTerri Gelbart
Molecular and Experimental Medicine
6 shared publicationsCarol West
5 shared publications- Jaroslav Truksa
Laboratory of Tumour Resistance, Institute of Biotechnology, BIOCEV Research Center, Czech Academy of Sciences, Vestec, Czech Republic
5 shared publications - Jackson Clayborn Barton
Department of Medicine The University of Alabama at Birmingham Birmingham Alabama USA
3 shared publications
Latest Publications
- 1 March 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 48 (3) , 173-178
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6
- 1 March 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 48 (3) , 173-178
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6
- 1 February 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 48 (2) , 124-127
Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion
- 1 February 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 48 (2) , 124-127
Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion
- Open Access
- 11 January 2012
- Published by Wiley in British Journal of Haematology
- Vol. 156 (3) , 415-416
Corrigendum
- 11 January 2012
- Published by Wiley in British Journal of Haematology
- Vol. 156 (3) , 415-416
Open AccessCorrigendum
- 31 January 2011
- Published by Wiley in British Journal of Haematology
- Vol. 152 (6) , 785-786
Response to the letter by Nicolas et al, BJH-2010-01422.
- 31 January 2011
- Published by Wiley in British Journal of Haematology
- Vol. 152 (6) , 785-786
Response to the letter by Nicolas et al, BJH-2010-01422.
- Open Access
- 16 July 2010
- Published by Wiley in British Journal of Haematology
- Vol. 151 (1) , 106-109
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency
- 16 July 2010
- Published by Wiley in British Journal of Haematology
- Vol. 151 (1) , 106-109
Open AccessEPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency
- 1 January 2010
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 44 (1) , 16-21
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia
- 1 January 2010
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 44 (1) , 16-21
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia
- 1 November 2009
- Published by S. Karger AG in Acta Haematologica
- Vol. 122 (2-3) , 87-96
Role of Matriptase-2 (TMPRSS6) in Iron Metabolism
Iron, an essential element for life, is regulated primarily at the level of uptake, storage, and transport in order to maintain sufficient availability for normal physiology. The key protein in iron homeostasis is a 25-amino-acid peptide, hepcidin, which modulates the amount of iron in the circulation by binding and promoting the degradation of the iron exporter ferroportin. Given the central importance of hepcidin, recent studies have focused on how iron is sensed and how the iron signal is transmitted to hepcidin. Mutations in a type II serine protease, matriptase-2/TMPRSS6, were recently identified to be associated with severe iron deficiency caused by inappropriately high levels of hepcidin expression. A key biologically relevant substrate for the proteolytic activity of matriptase-2/TMPRSS6 was found to be hemojuvelin, a cell surface protein that regulates hepcidin expression through a BMP/SMAD pathway. In this review, we discuss the putative role of matriptase-2/TMPRSS6 in iron homeostasis.
- 1 November 2009
- Published by S. Karger AG in Acta Haematologica
- Vol. 122 (2-3) , 87-96
Role of Matriptase-2 (TMPRSS6) in Iron Metabolism
Iron, an essential element for life, is regulated primarily at the level of uptake, storage, and transport in order to maintain sufficient availability for normal physiology. The key protein in iron homeostasis is a 25-amino-acid peptide, hepcidin, which modulates the amount of iron in the circulation by binding and promoting the degradation of the iron exporter ferroportin. Given the central importance of hepcidin, recent studies have focused on how iron is sensed and how the iron signal is transmitted to hepcidin. Mutations in a type II serine protease, matriptase-2/TMPRSS6, were recently identified to be associated with severe iron deficiency caused by inappropriately high levels of hepcidin expression. A key biologically relevant substrate for the proteolytic activity of matriptase-2/TMPRSS6 was found to be hemojuvelin, a cell surface protein that regulates hepcidin expression through a BMP/SMAD pathway. In this review, we discuss the putative role of matriptase-2/TMPRSS6 in iron homeostasis.
- 27 October 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (4) , 571-581
Suppression of the hepcidin‐encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase‐2/TMPRSS6
Summary: Hepcidin, the master regulator of enteric iron absorption, is controlled by the opposing effects of pathways activated in response to iron excess or iron attenuation. Iron excess is regulated through a pathway involving the cell surface receptor hemojuvelin (HFE2) that stimulates expression of the hepcidin encoding gene (HAMP). Iron attenuation is countered through a pathway involving the hepatocyte‐specific plasma membrane protease matriptase‐2 encoded by TMPRSS6, leading to suppression of HAMP expression. The non‐redundant function of hemojuvelin and matriptase‐2 has been deduced from the phenotype imparted by mutations of HFE2 and TMPRSS6, which cause iron excess and iron deficiency respectively. Hemojuvelin is positioned to be the ideal substrate for matriptase‐2. To examine the relationship between hemojuvelin and matriptase‐2 in vivo, we crossed mice lacking the protease domain of matriptase‐2 with mice lacking hemojuvelin. Mice lacking functional matriptase‐2 and hemojuvelin exhibited low Hamp (Hamp1) expression, high serum and liver iron, and high transferrin saturation. Surprisingly, the double mutant mice also exhibited lower levels of iron in the heart compared to hemojuvelin‐deficient mice, demonstrating a possible cardioprotective effect resulting from the loss of matriptase‐2. This phenotype is consistent with hemojuvelin being a major substrate for matriptase‐2/TMPRSS6 protease activity.
- 27 October 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (4) , 571-581
Suppression of the hepcidin‐encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase‐2/TMPRSS6
Summary: Hepcidin, the master regulator of enteric iron absorption, is controlled by the opposing effects of pathways activated in response to iron excess or iron attenuation. Iron excess is regulated through a pathway involving the cell surface receptor hemojuvelin (HFE2) that stimulates expression of the hepcidin encoding gene (HAMP). Iron attenuation is countered through a pathway involving the hepatocyte‐specific plasma membrane protease matriptase‐2 encoded by TMPRSS6, leading to suppression of HAMP expression. The non‐redundant function of hemojuvelin and matriptase‐2 has been deduced from the phenotype imparted by mutations of HFE2 and TMPRSS6, which cause iron excess and iron deficiency respectively. Hemojuvelin is positioned to be the ideal substrate for matriptase‐2. To examine the relationship between hemojuvelin and matriptase‐2 in vivo, we crossed mice lacking the protease domain of matriptase‐2 with mice lacking hemojuvelin. Mice lacking functional matriptase‐2 and hemojuvelin exhibited low Hamp (Hamp1) expression, high serum and liver iron, and high transferrin saturation. Surprisingly, the double mutant mice also exhibited lower levels of iron in the heart compared to hemojuvelin‐deficient mice, demonstrating a possible cardioprotective effect resulting from the loss of matriptase‐2. This phenotype is consistent with hemojuvelin being a major substrate for matriptase‐2/TMPRSS6 protease activity.
- 1 February 2009
- Published by Annual Reviews in Annual Review of Pathology: Mechanisms of Disease
- Vol. 4 (1) , 489-515
Regulation of Hepcidin and Iron-Overload Disease
Hepcidin, a 25-amino-acid antimicrobial peptide, is the central regulator of iron homeostasis. Hepcidin transcription is upregulated by inflammatory cytokines, iron, and bone morphogenetic proteins and is downregulated by iron deficiency, ineffective erythropoiesis, and hypoxia. The iron transporter ferroportin is the cognate receptor of hepcidin and is destroyed as a result of interaction with the peptide. Except for inherited defects of ferroportin and hepcidin itself, all forms of iron-storage disease appear to arise from hepcidin dysregulation. Studies using multiple approaches have begun to delineate the molecular mechanisms that regulate hepcidin expression, particularly at the transcriptional level. Knowledge of the regulation of hepcidin by inflammation, iron, erythropoiesis, and hypoxia will lead to an understanding of the pathogenesis of primary hemochromatosis, secondary iron overload, and anemia of inflammatory disease.
- 1 February 2009
- Published by Annual Reviews in Annual Review of Pathology: Mechanisms of Disease
- Vol. 4 (1) , 489-515
Regulation of Hepcidin and Iron-Overload Disease
Hepcidin, a 25-amino-acid antimicrobial peptide, is the central regulator of iron homeostasis. Hepcidin transcription is upregulated by inflammatory cytokines, iron, and bone morphogenetic proteins and is downregulated by iron deficiency, ineffective erythropoiesis, and hypoxia. The iron transporter ferroportin is the cognate receptor of hepcidin and is destroyed as a result of interaction with the peptide. Except for inherited defects of ferroportin and hepcidin itself, all forms of iron-storage disease appear to arise from hepcidin dysregulation. Studies using multiple approaches have begun to delineate the molecular mechanisms that regulate hepcidin expression, particularly at the transcriptional level. Knowledge of the regulation of hepcidin by inflammation, iron, erythropoiesis, and hypoxia will lead to an understanding of the pathogenesis of primary hemochromatosis, secondary iron overload, and anemia of inflammatory disease.